MapLight Therapeutics, Inc. (MPLT)
| Market Cap | 566.90M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -92.43M |
| Shares Out | 43.64M |
| EPS (ttm) | -121.50 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 361,953 |
| Open | 12.65 |
| Previous Close | 12.81 |
| Day's Range | 12.24 - 13.07 |
| 52-Week Range | 12.24 - 20.86 |
| Beta | n/a |
| Analysts | Strong Buy |
| Price Target | 31.00 (+138.65%) |
| Earnings Date | Dec 9, 2025 |
About MPLT
MapLight Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company for patients suffering from debilitating central nervous system disorders. The company’s products include ML-007C-MA, a fixed-dose combination of an M 1 /M 4 muscarinic agonist for the treatment of schizophrenia and Alzheimer’s disease psychosis; ML-004 for the treatment of social communication deficit and/or irritability in autism spectrum disorder; ML-021 for the treatment of motor deficits in Parkinson’s disease; and ML-009, a G-protein-coupled receptor 52 pos... [Read more]
Analyst Summary
According to 4 analysts, the average rating for MPLT stock is "Strong Buy." The 12-month stock price target is $31.0, which is an increase of 138.65% from the latest price.
News
MapLight Therapeutics Announces Closing of Initial Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares
SAN FRANCISCO and BOSTON, Oct. 29, 2025 (GLOBE NEWSWIRE) -- MapLight Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on improving the lives of patients suffering from debilitati...
MapLight Therapeutics valued at $787 million as shares jump in Nasdaq debut
Shares of MapLight Therapeutics opened 11.8% above their offer price in their Nasdaq debut on Monday, giving the drug developer a $787 million valuation.
MapLight Therapeutics Announces Pricing of Initial Public Offering
SAN FRANCISCO and BOSTON, Oct. 26, 2025 (GLOBE NEWSWIRE) -- MapLight Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on improving the lives of patients suffering from debilitati...
US IPO Weekly Recap: 5 Small IPOs Debut, As Government Shutdown Drags On
Five small IPOs debuted and four SPACs listed this week as the government shutdown continues to complicate listings. Two sizable IPOs are scheduled for the week ahead, both of which launched after the...
MapLight Therapeutics Starts $100 Million IPO Effort For CNS Treatments
MapLight Therapeutics is a clinical-stage biopharma focused on CNS disorders and has filed for a $100 million U.S. IPO to fund its pipeline. MPLT's lead drug, ML-07C-MA, targets schizophrenia and Alzh...
MapLight Therapeutics IPO Registration Document (S-1)
MapLight Therapeutics has filed to go public with an IPO on the NASDAQ.
CNS disorder biotech MapLight Therapeutics files for a $100 million IPO
MapLight Therapeutics, a Phase 2 biotech developing therapies for neuropsychiatric and CNS disorders, filed on Friday with the SEC to raise up to $100 million in an initial public offering.